title: A case of cellulitis causing tissue defect during etanercept therapy.
abstract: Tumor necrosis factor-alpha (TNF-α) antagonists are employed increasingly during recent years in patients with active rheumatoid arthritis who do not respond to disease-modifying anti-rheumatic drugs. Contraindications such as infections, auto-antibody formation and hypersensitive reactions can be observed during the treatment with TNF-α antagonist drugs. Our case was a 52-year-old woman, followed by several centers for a period of 21 years with a seropositive, erosive and nodular RA diagnosis. Anti TNF-α treatment was commenced due to the failure to control the disease. During the treatment, a serious cellulite developed, which required hospitalization and surgical debridement as well as intravenous antibiotics treatment. Through the present case, we aimed to draw attention to the skin infection during the use of etanercept in a patient with RA.
authors.affiliation: Department of Physical Therapy and Rehabilitation, Ankara Diskapi Yildirim Beyazit Education and Research Hospital, Ministry of Health, Huzur mah 1157. sok 13-1/11 Dikmen Ankara Turkey, Ankara, Turkey. denizdulgeroglu@gmail.com
authors.forename: Dulgeroglu
authors.initials: D
authors.lastname: Deniz
authors.forename: Umay
authors.initials: U
authors.lastname: Ebru
authors.forename: Bal
authors.initials: B
authors.lastname: Ajda
authors.forename: Tetik Menevse
authors.initials: TM
authors.lastname: Gulsum
authors.forename: Tatlican
authors.initials: T
authors.lastname: Semih
authors.forename: Cakci
authors.initials: C
authors.lastname: Aytul
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002481:Cellulitis / Q000139:chemically induced* / Q000175:diagnosis* / Q000628:therapy; D003646:Debridement; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use*; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012307:Risk Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000900:Anti-Bacterial Agents; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept